Amneal Pharmaceuticals to Acquire Kashiv BioSciences: A New Era in Biosimilars

Amneal Pharmaceuticals and Kashiv BioSciences have signed a definitive acquisition agreement, poised to revolutionize the biosimilars sector globally. By combining Kashiv's deep R&D capabilities with Amneal's robust commercial infrastructure, the merger aims to deliver affordable, high-quality biologic therapies, enhancing market reach in the U.S. and internationally.

The transaction, pending shareholder and regulatory approvals, is set to conclude by late 2026. Once finalized, Amneal expects to integrate effectively with Kashiv, promising a streamlined platform for biosimilar production and commercialization, focusing on accelerating the pipeline of these essential medicines.

Amneal co-CEOs Chirag and Chintu Patel emphasized the strategic importance of the acquisition, positioning Amneal at the forefront of an expanding affordable medicines market. The merger not only reflects their shared commitment to health accessibility but also signifies a strategic push toward market leadership in the biosimilars space.